Fig 1.
Examples of specimens using the HPV16/18-E6 test.
(C) Control line; (16) HPV16-E6 line; (18) HPV-18-E6 line. Strip on left side (1): cervical sample HPV16 positive; Strip in the middle (2): cervical sample HPV18 positive; Strip on the right side (PC): positive control (HPV16/18 positive).
Table 1.
Number and percentage of cases according to cervical cytology, histology diagnosis, HPV-DNA test and HPV16/18-E6 test.
Table 2.
Agreement and association analyses of HPV16/18-E6 and HPV-DNA tests.
CI, confidence interval.
Table 3.
Performance of HPV16/18-E6 test, HPV-DNA test and cytology for the detection of CIN2+.
CI, confidence interval; AUC, area under ROC curve; ASCH+, Atypical Squamous Cells of Undetermined Significance or worse; HSIL, High-grade Squamous Intraepithelial Lesion. CIN2+: CIN2, CIN3, carcinoma in situ, invasive carcinoma, carcinoma not otherwise specified.
Table 4.
Performance of HPV16/18-E6 test, HPV-DNA test and cytology for the detection of CIN3+.
CI, confidence interval; AUC, area under ROC curve; ASCH+, Atypical Squamous Cells of Undetermined Significance or worse; HSIL, High-grade Squamous Intraepithelial Lesion. CIN3+: CIN3, carcinoma in situ, invasive carcinoma, carcinoma not otherwise specified.
Table 5.
Performance of different strategies for the detection of CIN2+.
CI, confidence interval; AUC, area under ROC curve; ASCH+, Atypical Squamous Cells of Undetermined Significance or worse; HSIL, High-grade Squamous Intraepithelial Lesion.
Table 6.
Performance of different strategies for the detection of CIN3+.
CI, confidence interval; AUC, area under ROC curve; ASCH+, Atypical Squamous Cells of Undetermined Significance or worse; HSIL, High-grade Squamous Intraepithelial Lesion.